Research ArticleCancer

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

See allHide authors and affiliations

Science Translational Medicine  12 Apr 2017:
Vol. 9, Issue 385, eaak9679
DOI: 10.1126/scitranslmed.aak9679

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Antitumor attack on two fronts

The use of immune checkpoint inhibitors and other immunotherapies for the treatment of cancer is continuing to expand as these drugs demonstrate effectiveness in progressively more cancer types and therapeutic contexts. At the same time, the drugs are not perfect, and not all patients respond to them, so a key subject of research in this field is determining optimal ways to combine immune checkpoint therapies with other cancer treatments. Schmittnaegel et al. and Allen et al. focused their studies on the combination of antiangiogenic treatments with checkpoint inhibitors. The authors demonstrated how inhibition of tumor angiogenesis can facilitate the access of cytotoxic T cells to tumors, while the checkpoint inhibitors protect these T cells from exhaustion, enhancing their antitumor effects.

View Full Text

Stay Connected to Science Translational Medicine